Felix Ratjen, MD
Felix is the Division Chief of Paediatric Respiratory Medicine at The Hospital for Sick Children, Professor of Paediatrics at The University of Toronto, Program Head and Senior Scientist at the Research Institute in the Translational Medicine research program. He is co-leading the CF Centre at SickKids. Felix’s main research interest is in cystic fibrosis lung disease including new therapeutic strategies to target the underlying defect, treatment of airway infections such as first infection with Pseudomonas aeruginosa, airway inflammation and other important aspects of the disease.
Harm Tiddens, MD
Harm Tiddens is a Professor in pediatric pulmonology at the ErasmusMC-Sophia Children’s Hospital and at the department of radiology. He is heading the research of the Sophia Cystic Fibrosis (CF)-center and of the ErasmusMC Lung Imaging Group (ELIG) focusing on the development of novel structure and function outcome measures and computational model systems to study chronic lung diseases. In 1997 he co-founded the European CF Society Clinical Trial Network (ECFS-CTN) that currently includes participation of over 17.500 CF patients and 43 CF centers.
Jochen Mainz, MD
Jochen is the head of the CF Centre and a Professor for Paediatric Pulmonology at Brandenburg Medical School (MHB), University, Germany. His research interests concern abdominal and sinonasal involvement in CF. With his team, he developed the CFAbd-Score, a validated CF-specific PROM for quantification of the multi-organic gastrointestinal symptoms.
Marion Rowland, MD
Marion is a clinical epidemiologist in the School of Medicine University College Dublin. Marion has had a long involvement with Cystic Fibrosis research. Since 2006, she has been the lead investigator for the Irish Longitudinal Study of Cystic Fibrosis Liver Disease, a unique national cohort study which aims to understand the risk factors and outcome for liver disease in CF.
Hartmut Grasemann, MD
Hartmut is a Professor of Paediatrics at the University of Toronto and staff respirologist at the Hospital for Sick Children (SickKids) in Toronto, Canada. Hartmut’s main research interest is in the L-arginine/nitric oxide (NO) metabolism and its role in CF lung disease.
Alexandra Quittner, PhD
Cliff Taggart, PhD
Cliff is Chair of Respiratory Cell and Molecular Biology at Queen’s University Belfast. His research focuses on CF innate immune response in the lung and how these become dysregulated during excessive inflammation as a result of elevated protease activity.
Paul Cotter, MD
Paul is the Head of Food Biosciences at Teagasc and a Principal Investigator with the APC Microbiome Ireland and Vistamilk SFI Centres as well as Food for Health Ireland. He also co-ordinates the EU H2020 Innovation Action relating to microbiomes and the food chain, MASTER (€10.9 mi budget). Paul also heads the Teagasc DNA high throughput sequencing facility. He is a molecular microbiologist, with a particular focus on the microbiology/microbiome of humans, animals, foods and the food chain. Paul is also the author of >300 peer-reviewed publications and was included in the Clarivate list of highly cited researchers for 2018 and 2019.
Billy Bourke, MD
Billy is a consultant paediatric gastroenterologist in CHI -Crumlin and Associate Professor of Gastroenterology in University College Dublin. He has a long-term interest in CF liver disease and together with Marion Rowland has published extensively on the epidemiology and outcome for Irish children with this condition.
Aiden McCormick, MD
Aiden is a consultant hepatologist in St Vincent’s University Hospital, Dublin. He is also a Newman Clinical Research Professor in University College Dublin and Clinical Lead for the National Hepatitis C Treatment Program in the HSE. Aiden’s main research interests are in chronic liver disease and portal hypertension.
Sinéad Weldon, PhD
Sinéad is a Senior Lecturer and Principal Investigator in the Wellcome-Wolfson Institute for Experimental Medicine, QUB. Sinéad has a long-standing interest in CF and her research programme is centred on the status, integrity and mechanisms of action of host defence proteins (antimicrobial peptides, antiproteases, proteases), how this activity may be compromised during disease and exploited for biomarker and therapeutic potential. As part of the RECOVER project, Sinéad’s group will analyse markers of airway inflammation, which will provide important information in terms of monitoring disease activity and burden in individuals with CF and will contribute to the profile of personalised responses to CFTR modulators.